KR20200018488A - 고암모니아혈증을 치료하기 위한 글루타민 합성효소의 용도 - Google Patents

고암모니아혈증을 치료하기 위한 글루타민 합성효소의 용도 Download PDF

Info

Publication number
KR20200018488A
KR20200018488A KR1020197038087A KR20197038087A KR20200018488A KR 20200018488 A KR20200018488 A KR 20200018488A KR 1020197038087 A KR1020197038087 A KR 1020197038087A KR 20197038087 A KR20197038087 A KR 20197038087A KR 20200018488 A KR20200018488 A KR 20200018488A
Authority
KR
South Korea
Prior art keywords
protein
ammonia
hyperammonemia
lowering agent
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197038087A
Other languages
English (en)
Korean (ko)
Inventor
타마라 니콜슨
Original Assignee
토리스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1708288.4A external-priority patent/GB201708288D0/en
Priority claimed from GBGB1800867.2A external-priority patent/GB201800867D0/en
Application filed by 토리스 게엠베하 filed Critical 토리스 게엠베하
Priority to KR1020257020185A priority Critical patent/KR20250093434A/ko
Publication of KR20200018488A publication Critical patent/KR20200018488A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53—Ligases (6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020197038087A 2017-05-24 2018-05-24 고암모니아혈증을 치료하기 위한 글루타민 합성효소의 용도 Ceased KR20200018488A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257020185A KR20250093434A (ko) 2017-05-24 2018-05-24 고암모니아혈증을 치료하기 위한 글루타민 합성효소의 용도

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1708288.4A GB201708288D0 (en) 2017-05-24 2017-05-24 Use of glutamine synthetase for treating hyperammonemia
GB1708288.4 2017-05-24
GB1800867.2 2018-01-19
GBGB1800867.2A GB201800867D0 (en) 2018-01-19 2018-01-19 Use of glutamine synthetase for treating hyperammonemia
PCT/GB2018/051415 WO2018215780A1 (en) 2017-05-24 2018-05-24 Use of glutamine synthetase for treating hyperammonemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257020185A Division KR20250093434A (ko) 2017-05-24 2018-05-24 고암모니아혈증을 치료하기 위한 글루타민 합성효소의 용도

Publications (1)

Publication Number Publication Date
KR20200018488A true KR20200018488A (ko) 2020-02-19

Family

ID=62492675

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197038087A Ceased KR20200018488A (ko) 2017-05-24 2018-05-24 고암모니아혈증을 치료하기 위한 글루타민 합성효소의 용도
KR1020257020185A Pending KR20250093434A (ko) 2017-05-24 2018-05-24 고암모니아혈증을 치료하기 위한 글루타민 합성효소의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257020185A Pending KR20250093434A (ko) 2017-05-24 2018-05-24 고암모니아혈증을 치료하기 위한 글루타민 합성효소의 용도

Country Status (11)

Country Link
US (4) US12359184B2 (enExample)
EP (3) EP4119133A1 (enExample)
JP (3) JP2020520677A (enExample)
KR (2) KR20200018488A (enExample)
CN (2) CN111093641A (enExample)
AU (2) AU2018272294B2 (enExample)
BR (1) BR112019024750A2 (enExample)
CA (1) CA3064352A1 (enExample)
IL (1) IL270817B2 (enExample)
MX (2) MX2019014027A (enExample)
WO (1) WO2018215780A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022005201A1 (ko) 2020-06-30 2022-01-06 경상국립대학교산학협력단 티로신을 유효성분으로 함유하는 단백질 내 티로신의 니트로화에 의한 질환의 예방, 개선 또는 치료용 조성물

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200018488A (ko) * 2017-05-24 2020-02-19 토리스 게엠베하 고암모니아혈증을 치료하기 위한 글루타민 합성효소의 용도
EP3856231A1 (en) * 2018-09-28 2021-08-04 Thoeris GmbH Use of glutamine synthetase for treating fatty liver disease
CN110133287B (zh) * 2019-05-22 2021-07-30 上海碧云天生物技术有限公司 蛋白抽提溶液及其应用
JP7865272B2 (ja) 2023-05-24 2026-05-26 トヨタ自動車株式会社 二次電池
CN118949035A (zh) * 2024-07-31 2024-11-15 北京大学第一医院(北京大学第一临床医学院) Glul生物标志物在心力衰竭诊断、治疗或预后预测中的应用
CN122075711A (zh) * 2026-04-24 2026-05-26 上海健康医学院 组蛋白去乙酰化酶抑制剂HDACi在制备预防和/或治疗高血氨诱发脑病的药物中的应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7590493B2 (en) 2000-07-31 2009-09-15 Ocimum Biosolutions, Inc. Methods for determining hepatotoxins
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6451547B1 (en) 2001-04-25 2002-09-17 Syn X Pharma Process for differential diagnosis of Alzheimer's dementia and device therefor
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
AUPR805101A0 (en) 2001-10-03 2001-10-25 University Of New South Wales, The A method of genetic screening using an amplifiable gene
JP2003225093A (ja) 2001-11-30 2003-08-12 Sumitomo Pharmaceut Co Ltd 軟骨障害マーカー及びその利用
US6875792B2 (en) 2002-01-31 2005-04-05 Mso Pharma Llc Dosage form of L-Methionine S-Sulfoximine
JP2003274963A (ja) 2002-03-22 2003-09-30 Japan Science & Technology Corp 遺伝子組換え細胞株及びそれを用いた肝機能補助装置
US20050074865A1 (en) * 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
AU2003303144A1 (en) 2002-10-18 2004-07-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003284357A1 (en) 2002-11-01 2004-06-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
WO2004106489A2 (en) 2003-05-21 2004-12-09 Divergence, Inc Nematode GS-like sequences
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20070098702A1 (en) * 2005-02-17 2007-05-03 University Of Maryland, Baltimore Recombinant protein polymer vectors for systemic gene delivery
EP1752143A1 (en) 2005-08-08 2007-02-14 NewThera Novel uses for drugs targeting glutamine synthetase
CA2634510C (en) 2005-12-21 2018-01-09 Universite Catholique De Louvain Isolated liver stem cells
RU2362572C2 (ru) 2007-07-17 2009-07-27 Юрий Георгиевич Каминский Способ снижения концентрации аммиака в крови с помощью аммоцитов и инкапсулированной глутаминсинтетазы
WO2009134460A1 (en) * 2008-04-29 2009-11-05 Hyperion Therapeutics Methods of treatment using ammonia-scavenging drugs
US9273296B2 (en) 2008-09-08 2016-03-01 Cellectis Meganuclease variants cleaving a DNA target sequence from a glutamine synthetase gene and uses thereof
WO2011147981A2 (en) 2010-05-28 2011-12-01 Mind-Nrg Sa Neuregulin isoforms, neuregulin polypeptides and uses thereof
WO2013020914A1 (en) * 2011-08-10 2013-02-14 Celares Gmbh Peg-conjugated peptides
KR101494072B1 (ko) 2012-03-12 2015-02-17 한화케미칼 주식회사 변이된 글루타민 합성효소 유전자를 포함하는 벡터 및 이를 이용한 목적 단백질의 생산방법
EP2674495A1 (en) 2012-06-14 2013-12-18 Sanofi CHO expression system
MX377806B (es) 2014-11-07 2025-03-11 Instituto Nac De Ciencias Medicas Y Nutricion Salvador Zubiran Uso de un baculovirus recombinante que media la expresión de la glutamina sintetasa para tratar la encefalopatía hepática.
KR20230018526A (ko) * 2014-11-24 2023-02-07 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
AU2016274311A1 (en) * 2015-06-10 2018-01-18 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
WO2017173043A1 (en) 2016-03-30 2017-10-05 Spark Therapeutics, Inc. Cell line for recombinant protein and/or viral vector production
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
JP6972022B2 (ja) 2016-05-11 2021-11-24 アムジエン・インコーポレーテツド グルタミンシンセターゼ遺伝子内相補ベクターを用いた高レベルのヘテロマータンパク質発現細胞の直接選択
CN110023500B (zh) 2016-11-16 2024-10-11 新加坡科技研究局 作为选择标记的减毒谷氨酰胺合成酶
KR20200018488A (ko) 2017-05-24 2020-02-19 토리스 게엠베하 고암모니아혈증을 치료하기 위한 글루타민 합성효소의 용도
US11479792B2 (en) 2017-07-13 2022-10-25 Upside Foods, Inc. Compositions and methods for increasing the efficiency of cell cultures used for food production
WO2019028273A1 (en) 2017-08-02 2019-02-07 Dna2.0, Inc. Dba Atum DNA VECTORS AND ELEMENTS FOR SUSTAINED GENE EXPRESSION IN EUKARYOTIC CELLS
CN109988777A (zh) 2017-12-29 2019-07-09 南京金斯瑞生物科技有限公司 谷氨酰胺合成酶基因以及应用
CN110714057A (zh) 2018-07-11 2020-01-21 成都金洛克生物技术有限公司 用于检测外源基因整合和定位的通用型fish探针及其应用
CN109504709B (zh) 2018-11-28 2020-07-24 上海安民生物技术有限公司 白蛋白启动子驱动的白蛋白表达载体
WO2020172659A1 (en) 2019-02-22 2020-08-27 Smith & Nephew, Inc. Combination electrosurgical and mechanical resection device
CA3137457A1 (en) 2019-05-07 2020-11-12 Amgen Inc. Vectors and expression systems for producing recombinant proteins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022005201A1 (ko) 2020-06-30 2022-01-06 경상국립대학교산학협력단 티로신을 유효성분으로 함유하는 단백질 내 티로신의 니트로화에 의한 질환의 예방, 개선 또는 치료용 조성물

Also Published As

Publication number Publication date
US20210145946A1 (en) 2021-05-20
CA3064352A1 (en) 2018-11-29
AU2024201089B2 (en) 2025-04-24
EP4295904A3 (en) 2024-02-28
JP7688926B2 (ja) 2025-06-05
AU2018272294B2 (en) 2024-05-23
EP3630077A1 (en) 2020-04-08
IL270817B2 (en) 2025-10-01
KR20250093434A (ko) 2025-06-24
WO2018215780A1 (en) 2018-11-29
BR112019024750A2 (pt) 2020-06-09
US12359184B2 (en) 2025-07-15
AU2024201089A1 (en) 2024-03-14
MX2024002249A (es) 2024-03-05
JP2020520677A (ja) 2020-07-16
MX2019014027A (es) 2020-08-03
CN111093641A (zh) 2020-05-01
US12338471B2 (en) 2025-06-24
IL270817B1 (en) 2025-06-01
US11932885B2 (en) 2024-03-19
IL270817A (en) 2020-01-30
US20240150746A1 (en) 2024-05-09
JP2023085301A (ja) 2023-06-20
JP2024059833A (ja) 2024-05-01
EP4295904A2 (en) 2023-12-27
CN118105471A (zh) 2024-05-31
US20220401532A1 (en) 2022-12-22
US20220401531A1 (en) 2022-12-22
AU2018272294A1 (en) 2020-01-16
EP4119133A1 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
JP7688926B2 (ja) 高アンモニア血症を治療するためのグルタミン合成酵素の使用
JP6621752B2 (ja) 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法
US20100062984A1 (en) Fgf-23 polypeptides
EP3967755B1 (en) Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
KR20250078598A (ko) 병리학적 석회화 병태를 치료하기 위한 조성물, 및 이의 사용 방법
CN112574982A (zh) 用于治疗高胱氨酸尿症的胱硫醚β-合酶
JP2026508800A (ja) ウリカーゼコンジュゲート及びその使用方法
JP2008500285A (ja) 塩ホメオスタシス及び／又は水分ホメオスタシスに伴う疾患のための治療薬及び診断薬としての、プロウログアニリン、及びそれに由来する合成類似体又はタンパク質分解切断産物
JP2015536658A (ja) 標的化イズロン酸−２−スルファターゼ化合物
HK40087273A (en) Glutamine synthetase protein conjugate
EA050582B1 (ru) Применение глутамин-синтетазы для лечения гипераммониемии
WO2020112565A1 (en) Antagonists of mitofusion 1 and beta ii pkc association for treating heart failure
US20230374091A1 (en) Annexin a5 compositions and methods
US12414986B2 (en) Use of glutamine synthetase for treating fatty liver disease
JP2016023959A (ja) インフラマソーム活性化制御物質のスクリーニング方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104